Apontis Pharma AG

XETRA APPH.DE

Apontis Pharma AG Cash and Short-Term Investments for the year ending December 31, 2023: USD 29.60 M

Apontis Pharma AG Cash and Short-Term Investments is USD 29.60 M for the year ending December 31, 2023, a -23.89% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • Apontis Pharma AG Cash and Short-Term Investments for the year ending December 31, 2022 was USD 38.89 M, a 14.48% change year over year.
  • Apontis Pharma AG Cash and Short-Term Investments for the year ending December 31, 2021 was USD 33.97 M, a 245.06% change year over year.
  • Apontis Pharma AG Cash and Short-Term Investments for the year ending December 31, 2020 was USD 9.84 M, a 18.76% change year over year.
  • Apontis Pharma AG Cash and Short-Term Investments for the year ending December 31, 2019 was USD 8.29 M.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
SV Wall Street
XETRA: APPH.DE

Apontis Pharma AG

CEO Mr. Bruno Wohlschlegel
IPO Date May 11, 2021
Location Germany
Headquarters Alfred-Nobel-Str. 10
Employees 177
Sector Healthcare
Industries
Pharmaceuticals Drugstores & Retail Pharmacies
Description

Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.

StockViz Staff

February 7, 2025

Any question? Send us an email